A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients
Oxaliplatin Accord Healthcare 5 mg/ml concentraat voor oplossing voor infusie
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Incidence of adverse events
Endpoint detail
Liver Disease Control Rate
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.